explore -WSS

explore

author：knowledge 2025-09-30 17:03:06 - browse：387

Wraparound views of downtown Boston enrich the employees at the new offices of Foundation Medicine in the Seaport District. — Lane Turner/Globe Staff

Contemporary paintings by artists who have overcome homelessness or disabilities greet visitors in the lobby. Upstairs in the cafeteria, employees order lunches served by local restaurants, including barbecued pulled pork sandwiches from Pennypacker’s. On the top floor, workers can savor a panoramic view of the Seaport District and downtown Boston.

This is the new headquarters of Foundation Medicine, a biotechnology firm that is consolidating its 1,100 Massachusetts employees into a new 16-story brick masonry building at 400 Summer St. Foundation, established in 2010 and later acquired by the Swiss drug giant Roche, had workers scattered among four locations, including its former headquarters in Cambridge.

About 800 workers have moved into the 630,000-square-foot building, which is kitty-corner from the Boston Convention and Exhibition Center, with the remaining 300 expected to arrive by early next year. No one seems happier about the long-planned consolidation than Dan Malarek, a 17-year veteran of Roche who became Foundation’s chief executive in December.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Pig kidney works a record two months in donated body

WSS

STAT readers on older presidents, polypills, Medicare, and more

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Regeneron agrees to White House price limits on anti

Long Covid needs a new name — and a new frame

Diverse clinical trials: Why aren’t we there yet?

He's a Nobel laureate. Critics say he was misleading on Covid

entertainment

explore

Wikipedia

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Alabama hospital puts IVF treatments on hold

The high cost of giving birth even with insurance

Obesity drugs seen as possible treatment for liver disease MASH

Hollywood unions extend contract negotiations for actors

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Drug repurposing or repositioning? The language matters

Acelyrin, a rare IPO success, stumbles in its first big test

Duchenne breakthrough therapy leaves behind pioneering families

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

leisure time

Dario to buy mental health app maker Twill in cash and stock deal

New Covid vaccine is recommended for everyone 6 months or older

Long Covid needs a new name — and a new frame

Antivenom research: Lessons from HIV applied in search for universal antidote

FDA proposes changes to key medical devices approval pathway

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

hotspot

hotspot

hotspot

leisure time